Angiotensin IV analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
== Drawbacks == There have been a few technical issues that have limited adoption of SFC technology in the past. First of all, is the need to keep a high gas pressure in the operating conditions. High-pressure vessels are expensive and bulky, and special materials are often needed to avoid dissolving gaskets and O-rings in the supercritical fluid. A second drawback is difficulty in maintaining pressure constant (by back-pressure regulation). Whereas liquids are nearly incompressible, so their densities are constant regardless of pressure, supercritical fluids are highly compressible and their physical properties change with pressure – such as the pressure drop across a packed-bed column. Currently, automated backpressure regulators can maintain a constant pressure in the column even if flow rate varies, mitigating this problem. A third drawback is difficulty in gas/liquid separation during collection of product. Upon depressurization, the CO2 rapidly turns into gas and aerosolizes any dissolved analyte in the process. Cyclone separators have lessened difficulties in gas/liquid separations.
=== Preservation === Archaeological work at Flag Fen is ongoing. Extensive drainage of the surrounding area, which benefits agriculture, means that many of the timbers are drying out and are threatened with destruction by such exposure. One section of poles is being preserved by replacing the cellulose in the wood with water-carried wax, impregnating the wood over the years. This technique is also being used to preserve Seahenge and the Hassholme Boat. Another preservation technique used for timbers found at the site is freeze drying. A well-organised visitor centre, the Flag Fen Bronze and Iron Age Centre, has been constructed there with a museum and exhibitions. In the preservation hall one section of the timbers is preserved in situ and prevented from drying out by misting with water. Also at the site are reconstructions of two Bronze Age roundhouses and one from the Iron Age. A section of the Roman road known as the Fen Causeway has been exposed and crosses the site. In addition there is a reconstruction of a prehistoric droveway used for moving livestock.
==== Pandemic unemployment fraud and debt ==== In January 2021, the Los Angeles Times reported that Newsom's administration had mismanaged $11.4 billion by disbursing unemployment benefits to ineligible claimants, especially those paid through the federally funded Pandemic Unemployment Assistance program. Another $19 billion in claims remained under investigation for fraud. At the same time, legitimate claimants faced lengthy delays in receiving benefits. The state's unemployment system had been overseen by California Labor Secretary Julie Su, a Newsom appointee, whom President Joe Biden later appointed as deputy secretary of labor in February 2021. Political opponents attributed the crisis to the Newsom administration's failure to heed multiple warnings by federal officials of the potential for fraud, while Newsom's administration said the Trump administration's failure to provide appropriate guidance for the new federally funded program contributed to the fraud. Experts said much of the fraud appeared to originate from international criminal gangs in 20 countries. A report by California State Auditor Elaine Howle said $810 million was disbursed to claimants who had fraudulently filed on behalf of inmates in the state's prison system. According to The Sacramento Bee, by the summer of 2021, California owed $23 billion to the federal government for unemployment benefits paid out during the pandemic, which was 43% of all unemployment debt, owed by 13 states at the time, to the federal government.
== Clinical significance == Cavin-2/SDPR is shown to act as a metastasis suppressor by xenograft studies utilizing breast cancer cell lines. Cavin-2 may elicit its metastasis suppressor function by directly interacting with ERK and limiting its pro-survival role. Moreover, it is suggested that cavin-2 is silenced during breast cancer progression by promoter DNA methylation. Metastasis suppressor role of cavin-2 may go beyond breast cancer since tumor samples from bladder, colorectal, lung, pancreatic, and ovarian cancers as well as sarcomas also exhibited loss of cavin-2 expression.
Sources: en.wikipedia.org
Professor Richard Hilary Templer. Lately Director of Innovation, Grantham Institute, Imperial College London. For services to Climate Innovation. Dr. Gillian Romaine Tett. Editorial Board, Financial Times. For services to Economic Journalism. Usha Ladwa-Thomas. Race Adviser, Welsh Government. For services to Black, Asian and Minority Ethnic Communities. Margaret Ann Throup, MP. Member of Parliament for Erewash. For Political and Public Service. Jane Elizabeth Toogood. Co-Chair, Hydrogen Delivery Council. For services to the Low Carbon Hydrogen Sector. Sara Louise Tough. Executive Director, Children's Services, Norfolk County Council. For services to Education and Children's Social Care. John Henry Trayner. Lately Managing Director, Go-Ahead London. For services to Transport, to Skills and to Education in London. Marcus Edward Trescothick. Mental Health Ambassador, Professional Cricketers' Association. For services to Mental Ill Health. Professor Joyce Ann Tyldesley. Professor of Egyptology, University of Manchester. For services to Egyptology and Heritage. Nicola Madeline van der Drift. Chief Executive, International Bomber Command Centre. For services to Heritage. Louise van der Straeten. Senior Lawyer, Serious Fraud Office. For services to the Administration of Justice. Vinaichandra Guduguntla Venkatesham. Chief Executive Officer, Arsenal Football Club. For services to Sport. Ewan Andrew Venters. Chief Executive, Hauser & Wirth and Chair, GREAT Private Sector Council. For services to International Trade. Robert Iain Wainwright. Founder, Doddie Aid.
Under CLIA, anyone, including patients and their families, laboratory personnel, and the general public, can submit anonymous complaints if there are concerns about the quality of laboratory testing. The most common CLIA complaints are concerns about a laboratory's operations, such as: unlabeled specimens, unqualified staff, record falsification, missing or incorrect test results and the confidentiality of patient information. For laboratories accredited by a laboratory Accreditation Organization (AO), complaints may be referred to the laboratory's AO. Though anyone may lodge a complaint, relatively few laboratory complaints have been filed. This may be due to a lack of publicity about complaint filing, since CLIA does not require that laboratory employees or patients be made aware of how to file a complaint, and to privacy concerns stemming from the lack of whistleblower protections. Other limiting factors include an increasing reliance on on-the-job (OTJ)- trained lab personnel who are unaware of regulatory requirements, foreign-sponsored H1b medical technologists fearing retaliatory deportation, and an aging workforce awaiting retirement. Laboratory whistleblowers may face countermeasures such as cover-ups, loss of income, position, or employment, punitive lawsuits, and attacks on their reputation, which would degrade their living conditions and dissuade them from bringing fraud to light. A June 2006 GAO report found that lab workers may file complaints infrequently due to concerns about retaliation and a lack of understanding of how to do so.
=== Psychiatric disorders === Beta blockers have been researched for treatment of a variety of psychiatric disorders besides anxiety disorders. These include depression, mania, acute stress disorder, post-traumatic stress disorder (PTSD), schizophrenia, aggression, and agitation. Beta blockers have also been used for the treatment of schizoid personality disorder. However, there is limited evidence supporting the efficacy of supplemental beta blocker use in addition to antipsychotic drugs for treating schizophrenia.
Sources: en.wikipedia.org
=== Post-Cold War === In late October 2019, a week before Commander of the Northern Fleet Aleksandr Moiseyev and Russian Foreign Minister Sergey Lavrov met their Norwegian counterparts in Kirkenes, Norway, ten submarines of Russia's Northern Fleet, among them two diesel-electric and eight non-strategic nuclear, left their homebases in the Kola Peninsula to participate in submarine drills that were the largest, on the Russian side, since Cold War operations Aport and Atrina. The main task of the submarines was reportedly testing Russian ability to breach the GIUK gap undetected and sail into the Atlantic Ocean. The drills were expected to last up to two months.
== Taxonomy == The Wagler's pit viper has undergone much taxonomic reclassification over the years and was previously placed in the genus Trimeresurus. However, its distinctly different morphology and venom characteristics set it apart, so that eventually a new genus was erected in which it was placed together with Hutton's viper, Tropidolaemus huttoni.
In 1994, an EU scientific commission was asked to report on the incidence of mastitis and other disorders in dairy cows and on other aspects of their welfare. The commission's statement, subsequently adopted by the EU, stated that the use of rBST substantially increased health problems with cows, including foot problems, mastitis, and injection site reactions, impinged on the welfare of the animals, and caused reproductive disorders. The report concluded, on the basis of the health and welfare of the animals, rBST should not be used. Health Canada prohibited the sale of rBST in 1999; the external committees found that there was health risk to humans, and the drug present a threat to animal health, and, for this reason, cannot be sold in Canada. Monsanto-sponsored trials reviewed by the FDA asked whether the use of rBST makes cows more susceptible to mastitis. According to the FDA, which used data from eight Monsanto-sponsored trials in its decision in 1993 to approve Monsanto's rBST product, the answer is yes. The data from these eight trials, which involved 487 cows, showed that during the period of rBST treatment, mastitis incidence increased by 76% in primiparous cows and by 50% for multiparous cows. Overall, the increase was 53%. Conversely, however, a study from the University of Georgia on the monitoring post-approval of rBST, showed that there was no statistically significant (P > 0.05) derivation in cases of clinical mastitis in dairy cows treated with rBST.
In 1868, the Japanese government established the Tokyo Arsenal. The same year, Ōmura Masujirō established Japan's first military academy in Kyoto. Ōmura further proposed military billets be filled by all classes of people including farmers and merchants. The shōgun class, not happy with Ōmura's views on conscription, assassinated him the following year. In 1870, Japan expanded its military production base by opening another arsenal in Osaka. The Osaka Arsenal was responsible for the production of machine guns and ammunition. Also, four gunpowder facilities were opened at this site. Japan's production capacity gradually expanded. In 1872, Yamagata Aritomo and Saigō Jūdō, both new field marshals, founded the Corps of the Imperial Guards. Also, in the same year, the hyobusho (war office) was replaced with a War Department and a Naval Department. The samurai class suffered great disappointment the following years, when in January the Conscription Law of 1873 was passed. This monumental law, signifying the beginning of the end for the samurai class, initially met resistance from both the peasant and warrior alike. The peasant class interpreted the term for military service, ketsu-eki (blood tax) literally, and attempted to avoid service by any means necessary. Avoidance methods included maiming, self-mutilation, and local uprisings. In conjunction with the new conscription law, the Japanese government began modeling their ground forces after the French military. Indeed, the new Japanese army used the same rank structure as the French.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.